Windtree Therapeutics Files Routine 8-K; No New Material Info
Ticker: WINTW · Form: 8-K · Filed: Jan 31, 2024 · CIK: 946486
| Field | Detail |
|---|---|
| Company | Windtree Therapeutics Inc /De/ (WINTW) |
| Form Type | 8-K |
| Filed Date | Jan 31, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Complexity: simple
Sentiment: neutral
Topics: administrative, corporate-governance, 8-K
TL;DR
**WINDTREE THERAPEUTICS filed a standard 8-K with no new news, just administrative details.**
AI Summary
This 8-K filing from Windtree Therapeutics, Inc. on January 31, 2024, is a routine 'Other Events' report, primarily updating administrative information such as its business address at 2600 Kelly Road, Suite 100, Warrington, Pennsylvania 18976, and confirming its Delaware incorporation. It also lists its common stock as registered on an exchange, though the specific exchange is not detailed. This filing is largely administrative and does not contain new financial or operational news, meaning it has minimal direct impact on current or prospective shareholders.
Why It Matters
This filing is administrative and does not contain new material information, so it has little to no immediate impact on the stock price or investment thesis.
Risk Assessment
Risk Level: low — This filing is purely administrative and does not introduce any new financial or operational risks.
Analyst Insight
Given this is a routine administrative filing with no new material information, a smart investor would likely take no immediate action based solely on this 8-K. It's important to monitor for future filings that contain substantive news.
Key Players & Entities
- Windtree Therapeutics, Inc. (company) — the registrant filing the 8-K
- January 31, 2024 (date) — date of earliest event reported and filing date
- Delaware (company) — state of incorporation for Windtree Therapeutics, Inc.
- 2600 Kelly Road, Suite 100, Warrington, Pennsylvania 18976 (company) — business address of Windtree Therapeutics, Inc.
- 001-39290 (dollar_amount) — Commission File Number for Windtree Therapeutics, Inc.
- 94-3171943 (dollar_amount) — I.R.S. Employer Identification No. for Windtree Therapeutics, Inc.
- 215-488-9300 (dollar_amount) — telephone number for Windtree Therapeutics, Inc.
FAQ
What is the purpose of this 8-K filing by Windtree Therapeutics, Inc.?
This 8-K filing is categorized under 'Other Events' and 'Financial Statements and Exhibits,' primarily serving to update administrative information and confirm the company's registration details as of January 31, 2024.
What is the current business address of Windtree Therapeutics, Inc. as stated in the filing?
The current business address of Windtree Therapeutics, Inc. is 2600 Kelly Road, Suite 100, Warrington, Pennsylvania 18976, with a business phone number of (215) 488-9300.
What is the state of incorporation for Windtree Therapeutics, Inc.?
Windtree Therapeutics, Inc. is incorporated in Delaware, as indicated by 'State or other jurisdiction of incorporation or organization: Delaware' in the filing.
Does this 8-K filing contain any new financial or operational news that would impact investors?
No, this 8-K filing is a routine administrative update and does not contain any new financial results, operational changes, or other material news that would typically impact investors. It is filed under 'Other Events' and primarily confirms existing registration details.
What type of securities are registered pursuant to Section 12(b) of the Act for Windtree Therapeutics, Inc.?
The filing states that 'Common Stock' is registered pursuant to Section 12(b) of the Act, though the specific exchange on which it is registered is not detailed in this document.
Filing Stats: 471 words · 2 min read · ~2 pages · Grade level 10.1 · Accepted 2024-01-31 08:00:12
Key Financial Figures
- $0.001 — h registered Common Stock , par value $0.001 per share WINT The Nasdaq Capital Ma
Filing Documents
- wint20240130_8k.htm (8-K) — 26KB
- ex_621095.htm (EX-99.1) — 12KB
- 0001437749-24-002612.txt ( ) — 172KB
- wint-20240131.xsd (EX-101.SCH) — 3KB
- wint-20240131_def.xml (EX-101.DEF) — 11KB
- wint-20240131_lab.xml (EX-101.LAB) — 15KB
- wint-20240131_pre.xml (EX-101.PRE) — 11KB
- wint20240130_8k_htm.xml (XML) — 3KB
01
Item 8.01 Other Events. On January 31, 2024, Windtree Therapeutics, Inc. (the "Company") issued a press release announcing that it has engaged Ladenburg Thalmann & Co. Inc. to evaluate strategic alternatives for the Company with the goal of maximizing stockholder value. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits The following exhibits are being filed herewith: Exhibit No. Document 99.1 Press Release of Windtree Therapeutics, Inc., dated January 31, 2024 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Dated: January 31, 2024 Windtree Therapeutics, Inc. By: /s/ Craig E. Fraser Name: Craig E. Fraser Title: President and Chief Executive Officer